Search for:

Isabella Liu

Dr. Isabella Liu is the head of the Firm's Asia Pacific Healthcare Industry Group. She advises clients on matters relating to the creation, exploitation and protection of IP rights. She is also responsible for the local IP Group’s China and Hong Kong patent prosecution matters. Dr. Liu is ranked as a leading lawyer in her field by top legal directories such as Chambers Asia Pacific for the Life Sciences category and IAM Patent. She has been complimented by clients that she possesses “a superb ability to understand the most complex technologies” and was noted for "advis[ing] in a way that is very commercial and strategic."

Baker McKenzie’s TMT Looking Ahead 2022 five-part series explores key themes, offers timely insights, and lays out recommendations for technology, media and telecommunication companies looking to navigate the latest industry developments. Topics covered include tech regulation and compliance, tech M&A, interactive entertainment, 5G and TMT as the driver of change.

The latest iteration of our annual Digital Transformation and Cloud Survey features insights from 500 global respondents, who cite heightened attention on and investment in cybersecurity, AI and the cloud as indicators of digital transformation being an integral part of enterprise thinking and planning. In this report, we provide these results together with insights from our almost decade of surveying the marketplace and thought leadership in digital transformation and cloud.

On 1 August 2021, the regulatory framework for Advanced Therapy Products (ATPs) came into operation in Hong Kong. ATPs, which are innovative medical products based on genes, cells and tissues that have been subject to ‘substantial manipulation’ or are intended for non-homologous use, have been added to the definition of ‘pharmaceutical products’ under the existing Pharmacy and Poisons Ordinance and its subsidiary legislation, the Pharmacy and Poisons Regulations.

Click to read Digital healthcare, a globally booming market, has been catalyzed by the events of COVID-19. In Asia Pacific, in particular, a rapidly expanding population, an empowered and tech-savvy middle class and physician shortage has created the perfect conditions for digital health innovation. A new era of digital healthcare…

With the healthcare and life sciences sector at the heart of the pandemic, we are seeing some new issues arising in the already complex world of life sciences collaborations, for both coronavirus-related and other products and therapies. The Life Sciences Collaborations: Key Considerations in the COVID-19 Era document is a…

In brief As the 2019 Novel Coronavirus (COVID-19) continues to spread across the world, the challenges for companies operating in the healthcare and life sciences sector are increasing. Below is a list of some of the risks emerging and evolving for companies in this sector. Read the checklist here.

On 7 April 2015, the State Administration for Industry and Commerce (“SAIC”) published the long awaited Regulation on the Prohibition of Conduct Eliminating or Restricting Competition by Abusing Intellectual Property Rights (the “Rules”), which will come into effect on 1 August 2015. The Rules are the first set of regulations…